Injection drug use and hepatitis C infection

2003 ◽  
Author(s):  
Kathryn Macomber ◽  
Garry Goza
Keyword(s):  
Hepatitis C ◽  
Drug Use ◽  
Injection Drug Use ◽  
Injection Drug ◽  
Hepatitis C Infection

The natural history of hepatitis C infection acquired through injection drug use: Meta-analysis and meta-regression

2010 ◽  
Vol 53 (2) ◽  
pp. 245-251 ◽  
Author(s):  
Ava John-Baptiste ◽  
Murray Krahn ◽  
Jenny Heathcote ◽  
Audery Laporte ◽  
George Tomlinson
Keyword(s):  
Hepatitis C ◽  
Drug Use ◽  
Natural History ◽  
Injection Drug Use ◽  
Meta Analysis ◽  
Injection Drug ◽  
Hepatitis C Infection ◽  
History Of ◽  
Meta Regression

Factors Associated With Hepatitis C Infection Among HIV-Infected Men Who Have Sex With Men With No Reported Injection Drug Use in New York City, 2000–2010

2015 ◽  
Vol 42 (7) ◽  
pp. 382-386 ◽  
Author(s):  
Alexander Breskin ◽  
Ann Drobnik ◽  
Preeti Pathela ◽  
Christine Chan ◽  
Sarah Braunstein ◽  
...  
Keyword(s):  
New York ◽  
New York City ◽  
Hepatitis C ◽  
Drug Use ◽  
Injection Drug Use ◽  
York City ◽  
Injection Drug ◽  
Hepatitis C Infection ◽  
Factors Associated ◽  
Sex With Men

scholarly journals Hepatitis C infection and injection drug use: The role of hepatologists in evolving treatment efforts

Hepatology ◽  
2004 ◽  
Vol 40 (3) ◽  
pp. 516-519 ◽  
Author(s):  
Thomas F. Kresina ◽  
Leonard B. Seeff ◽  
Henry Francis
Keyword(s):  
Hepatitis C ◽  
Drug Use ◽  
Injection Drug Use ◽  
Injection Drug ◽  
Hepatitis C Infection

scholarly journals Factors Associated with Prevalent Hepatitis C Infection Among HIV-Infected Women with No Reported History of Injection Drug Use: The Women's Interagency HIV Study (WIHS)

2009 ◽  
Vol 23 (11) ◽  
pp. 915-923 ◽  
Author(s):  
Toni Frederick ◽  
Pamela Burian ◽  
Norah Terrault ◽  
Mardge Cohen ◽  
Michael Augenbraun ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Drug Use ◽  
Injection Drug Use ◽  
Injection Drug ◽  
Hepatitis C Infection ◽  
Factors Associated ◽  
History Of

scholarly journals Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals

2015 ◽  
Vol 69 (3) ◽  
pp. 348-354 ◽  
Author(s):  
Margaret T. May ◽  
Amy C. Justice ◽  
Kate Birnie ◽  
Suzanne M. Ingle ◽  
Colette Smit ◽  
...  
Keyword(s):  
Risk Factors ◽  
Hepatitis C ◽  
Drug Use ◽  
Injection Drug Use ◽  
Injection Drug

Significant differences in clinical outcomes between HIV-hepatitis C virus coinfected individuals with and without injection drug use history

AIDS ◽  
2014 ◽  
Vol 28 (1) ◽  
pp. 121-127 ◽  
Author(s):  
Angela Cescon ◽  
Keith Chan ◽  
Janet M. Raboud ◽  
Ann N. Burchell ◽  
Jamie I. Forrest ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Drug Use ◽  
Clinical Outcomes ◽  
Injection Drug Use ◽  
Injection Drug

scholarly journals The hepatitis C epidemic in Canada: An overview of recent trends in surveillance, injection drug use, harm reduction and treatment

2021 ◽  
Vol 47 (12) ◽  
pp. 505-514
Author(s):  
Lillian Lourenço ◽  
Marian Kelly ◽  
Jill Tarasuk ◽  
Kyla Stairs ◽  
Maggie Bryson ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Drug Use ◽  
Harm Reduction ◽  
Injection Drug Use ◽  
Injection Drug ◽  
Health Concern ◽  
Prescription Opioid ◽  
Direct Acting Antiviral ◽  
Life Years ◽  
Hcv Transmission

Hepatitis C continues to be a significant public health concern in Canada, with the hepatitis C virus (HCV) responsible for more life-years lost than all other infectious diseases in Canada. An increase in reported hepatitis C infections was observed between 2014 and 2018. Here, we present changing epidemiological trends and discuss risk factors for hepatitis C acquisition in Canada that may have contributed to this increase in reported hepatitis C infections, focusing on injection drug use. We describe a decrease in the use of borrowed needles or syringes coupled with an increase in using other used injection drug use equipment. Also, an increased prevalence of injection drug use and use of prescription opioid and methamphetamine injection by people who inject drugs (PWID) may be increasing the risk of HCV acquisition. At the same time, while harm reduction coverage appears to have increased in Canada in recent years, gaps in access and coverage remain. We also consider how direct-acting antiviral (DAA) eligibility expansion may have affected hepatitis C rates from 2014 to 2018. Finally, we present new surveillance trends observed in 2019 and discuss how the coronavirus disease 2019 (COVID-19) pandemic may affect hepatitis C case counts from 2020 onwards. Continual efforts to i) enhance hepatitis C surveillance and ii) strengthen the reach, effectiveness, and adoption of hepatitis C prevention and treatment services across Canada are vital to reducing HCV transmission among PWID and achieving Canada’s HCV elimination targets by 2030.

Injection Drug Use and Hepatitis C: From Transmission to Treatment

2003 ◽  
Vol 33 (6) ◽  
pp. 377-382 ◽  
Author(s):  
Diana L Sylvestre
Keyword(s):  
Hepatitis C ◽  
Drug Use ◽  
Injection Drug Use ◽  
Injection Drug
Sign in / Sign up

Export Citation Format

Share Document